Next Article in Journal
Reflecting on Palliative Care Integration in Canada: A Qualitative Report
Previous Article in Journal
Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease
Article

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice

1
Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX 75251, USA
2
UPMC Hillman Cancer Center, Magee-Womens Hospital, Pittsburgh, PA 15232, USA
3
Genentech, Inc., South San Francisco, CA 94080, USA
4
Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL 32610, USA
5
F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland
6
Genesis Research, Hoboken, NJ 07030, USA
7
National Center for Tumor Disease, Heidelberg University Hospital and German Cancer Research, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Current affiliation: Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
Received: 14 June 2021 / Revised: 14 July 2021 / Accepted: 15 July 2021 / Published: 17 July 2021
(This article belongs to the Section Medical Oncology)
We investigated first-line (1L) treatment patterns and predictors of taxane use to better understand the evolving metastatic triple-negative breast cancer (mTNBC) treatment landscape. This retrospective analysis of the Truven Health MarketScan® (Somers, NY, USA) Database included women with mTNBC who received 1L therapy within six months of diagnosis (January 2005–June 2015). Multivariate logistic regression models identified predictors of taxane use, adjusting for prognostic factors. A total of 2271 women with newly diagnosed mTNBC received 1L treatment during the study period. Half received a 1L taxane (53%), more often in combination than as monotherapy (58% versus 42%), though this varied by specific taxane. Nab-Paclitaxel monotherapy increased substantially after 2010. More recent treatment year (odds ratio, 2.16 (95% CI 1.69–2.76]) and number of metastases (≥3 versus 1: 1.73 (1.25–2.40)) predicted taxane monotherapy versus combination. Having a health maintenance organization versus a preferred provider organization plan predicted less nab-paclitaxel versus paclitaxel (0.32 (0.13–0.80)) or docetaxel (0.30 (0.10–0.89)) use. More recent index year (2011–2015 vs. 2005–2010) was the only predictor favoring nab-paclitaxel versus paclitaxel (2.01 (1.26–3.21)) or docetaxel (3.63 (2.11–6.26)). Taxane-containing regimens remained the most common 1L mTNBC treatments. Paclitaxel and nab-paclitaxel use changed substantially over time, with nab-paclitaxel use associated with insurance coverage. View Full-Text
Keywords: metastatic triple-negative breast cancer; chemotherapy; paclitaxel; nab-paclitaxel; docetaxel metastatic triple-negative breast cancer; chemotherapy; paclitaxel; nab-paclitaxel; docetaxel
Show Figures

Figure 1

MDPI and ACS Style

O’Shaughnessy, J.; Emens, L.A.; Chui, S.Y.; Wang, W.; Russell, K.; Lin, S.-W.; Flores Avile, C.; Luhn, P.; Schneeweiss, A. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. Curr. Oncol. 2021, 28, 2741-2752. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28040239

AMA Style

O’Shaughnessy J, Emens LA, Chui SY, Wang W, Russell K, Lin S-W, Flores Avile C, Luhn P, Schneeweiss A. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. Current Oncology. 2021; 28(4):2741-2752. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28040239

Chicago/Turabian Style

O’Shaughnessy, Joyce, Leisha A. Emens, Stephen Y. Chui, Wei Wang, Kenneth Russell, Shih-Wen Lin, Carlos Flores Avile, Patricia Luhn, and Andreas Schneeweiss. 2021. "Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice" Current Oncology 28, no. 4: 2741-2752. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28040239

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop